The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
The clinical and endocrine response to a depot preparation of the LH-RH analogue ICI 118630 (Zoladex) was assessed in 55 untreated patients with advanced prostatic cancer. Whereas gonadal androgen suppression was achieved in all patients, subjective and objective clinical response occurred in only 69%, indicated by a relief of bone pain, a decrease in the size of the primary tumour and lymph node metastases and improvement in bone scan appearances. A third of these patients, however, subsequently showed progression of their disease. Serious side effects were not encountered in this study. The depot formulation is a simple, safe and convenient method of administering Zoladex and offers an alternative treatment for metastatic prostatic cancer.
D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001859:Bone Neoplasms / Q000097:blood / Q000188:drug therapy / Q000556:secondary*; D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D017273:Goserelin; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D011897:Random Allocation; D013739:Testosterone / Q000097:blood
D003692:Delayed-Action Preparations; D017273:Goserelin; D013739:Testosterone; D007986:Luteinizing Hormone; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D002064:Buserelin